Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01654497Phase 1Completed

Dexanabinol in Patients With Brain Cancer

Role: collaborator

NCT01489826Phase 1Completed

A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours

Role: lead

NCT02014363Phase 2Completed

Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)

Role: lead

NCT02054754Phase 1Completed

Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects

Role: lead

NCT02423239Phase 1Unknown

A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours

Role: lead

All 5 trials loaded